Previous 10 | Next 10 |
SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2021 after the market close on Monday, August 9, 2021. Ron Rocca, Exagen’s President and...
Exagen (XGN) announces that its lupus test showed promise in a multi-center study in patients suspected of the disease.AVISE lupus test showed "statistically significant" clinical utility in achieving a definitive SLE Diagnosis and positively impacts treatment decisions, the company said.The ...
SAN DIEGO, July 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the publication of their latest clinical utility study in Lupus & Science Medicine, found here: https://lupus.bmj.com/content/8/1/e0005...
SAN DIEGO, June 18, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, is proud to announce the company’s stockholders approved the election of Mr. Frank Stokes as an additional independent member to its Board of Directors at the A...
Exagen testing solutions for connective tissue disorders deliver advantages compared to traditional methods on the market. Ongoing adoption of the AVISE tests by healthcare providers with expanding insurance network coverage in the U.S. supports continued growth. The company is em...
SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 41st Annual Growth Stock Conference which takes place June 1-3, 2021. Ron Rocca, Exagen’s Presid...
The following slide deck was published by Exagen Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Exagen Inc. 2021 Q1 - Results - Earnings Call Presentation
Image source: The Motley Fool. Exagen Inc. (NASDAQ: XGN) Q1 2021 Earnings Call May 11, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Exagen Inc. (XGN) Q1 2021 Earnings Call Transcript
Exagen Inc. (XGN) Q1 2021 Results Conference Call May 11, 2021 04:30 PM ET Company Participants Mike Cavanaugh - IR Ron Rocca - President and CEO Kamal Adawi - CFO Mark Hazeltine - COO Conference Call Participants Chris Lin - Cowen Kyle Mikson - Cantor Fitzgerald Mark Massaro - BTIG Paul Knig...
Exagen (XGN): Q1 GAAP EPS of -$0.48 misses by $0.03.Revenue of $10.6M (+10.6% Y/Y) beats by $0.15M.Press Release For further details see: Exagen EPS misses by $0.03, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: Recognized total revenue of $14.4 million in the ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executiv...